# US 2010/0169993 A1 · Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0169993 A1
- Document ID: US20100169993A1
- Status: Published application
- Kind: A1
- Application number: 12/658,528
- Filed: 2010-02-10
- Published: 2010-07-01
- Earliest claimed: 2006-08-04
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Sanjiv S. Gambhir; Ramasamy Paulmurugan
- Web page: https://patentgrep.com/patent/US20100169993A1

## CPC

- C12Q 1/6897: involving reporter genes operably linked to promoters
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G01N 33/542: with steric inhibition or signal modification, e.g. fluorescent quenching
- G01N 33/743: {Steroid hormones}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2267/0393: Animal model comprising a reporter system for screening tests
- C07K 2319/00: Fusion polypeptide
- C12N 2830/002: inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- G01N 2333/723: Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
- Y10S 436/814: Pregnancy
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

Briefly described, embodiments of this disclosure include ligand-regulable transactivation systems, methods of producing ligand-regulable transactivation systems, methods of using ligand-regulable transactivation systems, reporter polynucleotides, method of producing reporter polynucleotides, activator fusion proteins, methods of producing activator fusion proteins, methods of regulating gene expression in vitro and in vivo for gene therapy, methods of screening estrogen receptor modulators with therapeutic treatments (e.g., anticancer, antiosteoporosis, and hormone replacement treatments), method of screening compounds (e.g., drugs and environmental pollutants) for the estrogenic effect, methods of evaluating the estrogen receptor pathway under different pathological conditions are provided, and the like.

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

A method of detecting a ligand, comprising:
providing an ligand-regulable transactivation system including; a reporter polynucleotide that includes a binding sequence, a promoter sequence, and a reporter sequence, wherein the binding sequence is connected with the promoter sequence and the promoter sequence is connected with the reporter sequence; and an activator fusion protein that includes a DNA binding domain, an estrogen receptor folding domain, and a transactivation domain, wherein the DNA binding domain is connected to the estrogen receptor folding domain, and the estrogen receptor folding domain is connected with the transactivation domain;
introducing a ligand to the system; and
detecting a bioluminescent signal in the presence of a bioluminescence initiating compound If the ligand causes the ER folding domain to change from a first conformational position to an interacting conformational position.

### Claim 15 (depends on 14)

The method of claim 14, wherein the method is conducted in vitro or in vivo.

### Claim 16 (depends on 14)

The method of claim 14, wherein the ligand is selected from: ER ligands, ER agonists, partial ER agonists, ER antagonists, partial ER antagonists, and selective estrogen receptor modulators.

### Claim 17

(canceled)

### Claim 18

A transgenic animal comprising:
a ligand-regulable transactivation system having:
a reporter polynucleotide that includes a binding sequence, a promoter sequence, and a reporter sequence, wherein the binding sequence is connected with the promoter sequence and the promoter sequence is connected with the reporter sequence; and
an activator fusion protein that includes a DNA binding domain, an estrogen receptor folding domain, and a transactivation domain, wherein the DNA binding domain is connected to the estrogen receptor folding domain, and the estrogen receptor folding domain is connected with the transactivation domain.

### Claim at position 7

19-28. (canceled)
